A proposal for measuring the degree of public health-sensitivity of patent legislation in the context of the WTO TRIPS Agreement

Bulletin of the World Health Organization

Volumn 85, Issue 1, 2007, Pages 49-56

  Chaves, Gabriela Costa ^a   Oliveira, Maria Auxiliadora ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

INTELLECTUAL PROPERTY RIGHTS; INTERNATIONAL AGREEMENT; MEDICINE; PUBLIC HEALTH; WORLD TRADE ORGANIZATION;

ARTICLE; CONSENSUS; DRUG INDUSTRY; DRUG LEGISLATION; HEALTH CARE POLICY; MEDICOLEGAL ASPECT; PATENT; QUESTIONNAIRE; SCORING SYSTEM; WORLD HEALTH ORGANIZATION;

CARIBBEAN REGION; DRUG INDUSTRY; HEALTH POLICY; HUMANS; INTERNATIONAL COOPERATION; LATIN AMERICA; PATENTS; PUBLIC HEALTH; WORLD HEALTH ORGANIZATION;

ATLANTIC ISLANDS; ATLANTIC OCEAN; CARIBBEAN ISLANDS; LATIN AMERICA;

EID: 33846207942     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.06.033274     Document Type: Article

References (43)

1. Bermudez JAZ, Oliveira MA, Chaves GC. Intellectual property in the context of the WTO TRIPS Agreement: what is at stake? In: Bermudez JAZ and Oliveira MA, eds. Intellectual property in the context of the WTO TRIPS Agreement: challenges for public health. Rio de Janeiro: ENSP/FIOCRUZ; 2004;23-61.
2. Pavitt K. Sectoral patterns of technical change: towards a taxonomy and a theory. Research policy 1984;13:343-73.
3. Outterson K. Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale j health policy law ethics. 2005;5(1):193-291.
4. Gontijo C. Propriedade industrial no século xxi - direitos desiguais. Brasília; 2003.
5. Hasenclever I. Diagnóstico da indústria farmacêutica brasileira. Rio de Janeiro: UNESCO/FUJB/IE-UFRJ; 2002.
6. Reis ALA. Bermudez JAZ. Aspectos econômicos: mercado farmacêutico e preço de medicamentos. In: Bermudez JAZ, Oliveira MA, Esher A, eds. Acceso a medicamentos: derecho fundamental, papel del estado. Rio de Janeiro: ENSP/FIOCRUZ; 2004;139-155.
7. World Health Organization, Health Action International. Medicine prices: a new approach to measurement. Geneva: WHO/HAI; 2003;152.
8. Luiza VL, Bermudez JAZ. Acesso a medicamentos: conceitos e polêmicas. In: Bermudez JAZ, Esher A, eds. Acceso a medicamentos: derecho fundamental, papel del estado. Rio de Janeiro: ENSP/FIOCRUZ;2004:45-67.
9. How to implement and develop a national drug policy. 2nd ed. Geneva: WHO, 2001.
10. Commission on Intellectual Property Rights. Integrating intellectual property rights and development policy. London: Commission on Intellectual Property Rights; 2002.
11. Coriat B, Orsi F, Hasenclever L, Fialho B, Tigre P. Intellectual property rights, anti-AIDS policy and generic drugs. Lessons from the Brazilian public health program. In: International AIDS Economics Network. Economics of AIDS and access to HIV/AIDS care in developing countries: issues and challenges: IAEN; 2003:110-135.
12. Oliveira MA, Esher A. Acesso universal ao tratamento para as pessoas vivendo com HIV e AIDS no Brasil. In: Bermudez JAZ, Esher A, eds. Acceso a medicamentos: derecho fundamental, papel del estado. Rio de Janeiro: ENSP/FIOCRUZ;2004:233-250.
13. Chequer P. Access to treatment and prevention: Brazil and beyond. In: International AIDS Society Conference, Rio de Janeiro; 2005.
14. Grangeiro A, Teixeira L, Bastos FI, Teixeira P. Sustainability of Brazilian policy for access to antiretroviral drugs. Rev saúde pública 2006;40(supl): 1-9.
15. Correa CM. Formulating effective pro-development national intellectual property policies. In: Bellmann C DG, Meléndez-ortiz R, eds. Trading in knowledge. Development perspectives on TRIPS, trade and sustainability. London: Earthscan Publications Ltd; 2003:209-217.
16. Oliveira MA, Bermudez JAZ, Chaves GC, Velásquez G. Has the implementation of the TRIPS agreement in Latin America and the Caribbean produced intellectual property legislation that favors public health? Bull World Health Organ 2004;82:815-21.
17. Correa CM. Integrating public health concerns into patent legislation in developing countries. Geneva: South Centre; 2000.
18. Musungu SF, Villaneuva S, Blasetti R. Utilizing TRIPS flexibilities for public health protection through South-South regional frameworks. Geneva: South Centre; 2004.
19. Bermudez JAZ, Epsztein R, Oliveira MA, Hasenclever L. O acordo TRIPS da OMC e a proteção patentária no Brasil: mudanças recentes e implicações para a produção local e o acesso da população aos medicamentos. Rio de Janeiro: ENSP/FIOCRUZ; 2000.
20. Thorpe P. Study on the implementation of the TRIPS agreement by developing countries. London: CIPR; 2002.
21. Keyla BK. Review of national patent legislations of India, Indonesia, Sri Lanka and Thailand. New Delhi: National Working Group on Patent Laws; 2003.
22. Oliveira MA, Chaves GC, Epsztein R. Brazilian intellectual property legislation. In: Bermudez JAZ, Oliveira MA eds. Intellectual property in the context of the WTO TRIPS Agreement: challenges for public health. Rio de Janeiro: ENSP/FIOCRUZ; 2004:151-160.
23. Chaves GC. Oliveira MA. WTO TRIPS Agreement implementation in Latin America and the Caribbean. In: Bermudez JAZ, Oliveira MA eds. Intellectual property in the context of the WTO TRIPS Agreement: challenges for public health. Rio de Janeiro: ENSP/FIOCRUZ; 2004:117-125.
24. Musungu SF, Oh C. The use of flexibilities in TRIPS by developing countries: can they promote access to medicines? Geneva: South Centre/WHO; 2006.
25. Souza LEPF, Silva LMV, Hartz ZMA, Paim JS. Conferência de consenso sobre a imagem-objetivo da descentralização da atenção à saúde no Brasil. In: Hartz Z, Vieirada-Silva L, eds. Avaliação em saúde: dos modelos teóricos à prática na avaliação de programas e sistemas de saúde. Salvador, Rio de Janeiro: EDUFBA, Editora Fiocruz; 2005:275.
26. Spínola AWP. Delfos: proposta tecnológica alternativa. São Paulo: Faculdade de Saúde Pública/ Universidade de São Paulo; 1984.
27. Spínola AWP. Técnica prospectiva delphi: abordagem teórico-prática. São Paulo: Faculdade de Saúde Pública/Universidade de São Paulo; 1997.
28. Drahos P. Bilateralism in intellectual property. London: Oxfam; 2001.
29. Cosendey MAE, Hartz ZMA, Bermudez JAZ. Validation of a tool for assessing the quality of pharmaceutical services. Reports in Public Health 2003;19:395-406.
30. Jorge MF. TRIPS-plus provisions in trade agreements and their potential adverse effects on public health. Journal of Generic Medicines 2004;i:199-211.
31. Oxfam. Undermining access to medicines: comparison of five US FTAs. In. London: Oxfam International; 2004.
32. Médicos sem fronteiras. Negociando a saúde: propriedade intelectual e acesso a medicamentos no acordo da área de livre comércio das Américas. Rio de Janeiro: MSF; 2003.
33. Song of the sirens: why the US - Andean FTAs undermine sustainable development and regional integration. Oxfam briefing paper, June 2006.
34. Correa CM. Implications of bilateral free trade agreements on access to medicines. Bull World Health Org 2006;84:399-404.
35. Oliveira MA, Santos EM, Mello JMC. AIDS, ativismo e regulaçã o de ensaios clínicos no Brasil: o protocolo 028. Cad. Saúde pública 1 2001; 17(4): 863-875.
36. World Intellectual Property Organization. Collection of laws for electronic access (CLEA). 23 jan 06. Available at http://www.wipo.int/clea/ en/
37. America Free Trade Agreement. National legislation. 23 jan 06. Available at www.ftaa-alca.org
38. Correa CM. Tendencias en el patenteamento farmacéutico. Buenos Aires: Corrigidor, 2001.
39. United States Trade Representative. NAFTA (North American Free Trade Agreement). Legal texts. Available at http://www.ustr.gov/trade_agreements/ regional/nafta/section_index.html
40. United States Trade Representative. Dominican Republic, Central America and United States Free Trade Agreement. Available at http://www.ustr.gov/trade_agreements/bilateral/cafta/section_index.html
41. Pimenta C, Terto Jr V, Kamel L, Maksud I, Raxach JC. Access to AIDS treatment in Bolivia and Paraguay: international cooperation and social mobilization. Rio de Janeiro: Brazilian Interdisciplinary AIDS Association, 2006.
42. Rittner D. Ação do ministério público ameaça patente de droga da Abbot contra HIV. Brasília: Valor Econômico, 2005.
43. Lawyers Collective HIV/AIDS Unit. Patent oppositions. Available at http://lawyerscollective.org/lc_hivaids/amtc/folder.2005-12-20.2101894352